Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Update on inspection by United States Food & Drug Administration (USFDA)
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The USFDA inspected Supriya Lifescience's Lote manufacturing facility in Maharashtra from February 2 to February 6, 2026. The inspection ended with a Form 483 containing just one minor observation. The company says it has already addressed that observation and received the Establishment Inspection Report (EIR) classified as 'Voluntary Action Indicated (VAI)'. VAI is a positive outcome that signals successful closure of the inspection without any mandatory corrective action. The company has reaffirmed its commitment to cGMP compliance across all facilities.
This is a positive outcome for shareholders — a clean VAI closure removes regulatory overhang and supports continued exports to the US market, which is a key revenue driver for the company.